Display options
Cite
Jain NK, Ishikawa TO, Spigelman I, et al. COX-2 expression and function in the hyperalgesic response to paw inflammation in mice. Prostaglandins Leukot Essent Fatty Acids. 2008;79(6):183-90doi: 10.1016/j.plefa.2008.08.001.
Jain, N. K., Ishikawa, T. O., Spigelman, I., & Herschman, H. R. (2008). COX-2 expression and function in the hyperalgesic response to paw inflammation in mice. Prostaglandins, leukotrienes, and essential fatty acids, 79(6), 183-90. https://doi.org/10.1016/j.plefa.2008.08.001
Jain, Naveen K, et al. "COX-2 expression and function in the hyperalgesic response to paw inflammation in mice." Prostaglandins, leukotrienes, and essential fatty acids vol. 79,6 (2008): 183-90. doi: https://doi.org/10.1016/j.plefa.2008.08.001
Jain NK, Ishikawa TO, Spigelman I, Herschman HR. COX-2 expression and function in the hyperalgesic response to paw inflammation in mice. Prostaglandins Leukot Essent Fatty Acids. 2008 Dec;79(6):183-90. doi: 10.1016/j.plefa.2008.08.001. Epub 2008 Oct 01. PMID: 18829279; PMCID: PMC2615797.
Copy Download .nbib Format: NLM
Share it on

Prostaglandins Leukot Essent Fatty Acids. 2008 Dec;79(6):183-90. doi: 10.1016/j.plefa.2008.08.001. Epub 2008 Oct 01.

COX-2 expression and function in the hyperalgesic response to paw inflammation in mice.

Prostaglandins, leukotrienes, and essential fatty acids

Naveen K Jain, Tomo-o Ishikawa, Igor Spigelman, Harvey R Herschman

Affiliations

  1. Department of Biological Chemistry, UCLA School of Medicine, 341 Boyer Hall, University of California, 611 Charles E. Young Drive East, Los Angeles, CA 90095, USA.

PMID: 18829279 PMCID: PMC2615797 DOI: 10.1016/j.plefa.2008.08.001

Abstract

Peripheral inflammation and edema are often accompanied by primary and secondary hyperalgesia which are mediated by both peripheral and central mechanisms. The role of cyclooxygenase-2 (COX-2)-mediated prostanoid production in hyperalgesia is a topic of substantial current interest. We have established a murine foot-pad inflammation model in which both pharmacologic and genetic tools can be used to characterize the role of COX-2 in hyperalgesia. Zymosan, an extract from yeast, injected into the plantar surface of the hindpaw induces an edema response and an increase in COX-2 expression in the hindpaw, spinal cord and brain. Zymosan-induced primary hyperalgesia, measured as a decrease in hindpaw withdrawal latency in response to a thermal stimulus, is long-lasting and is not inhibited by pre-treatment with the systemic COX-2 selective inhibitor, parecoxib (20 mg/kg). In contrast, the central component of hyperalgesia, measured as a reduction in tail flick latency in response to heat, is reduced by parecoxib. Zymosan-induced primary hyperalgesia in Cox-2-/- mice is similar to that of their Cox-2+/+ littermate controls. However, the central component of hyperalgesia is substantially reduced in Cox-2-/- versus Cox-2+/+ mice, and returns to baseline values much more rapidly. Thus pharmacological data suggest, and genetic experiments confirm, (i) that primary hyperalgesia in response to zymosan inflammation in the mouse paw is not mediated by COX-2 function and (ii) that COX-2 function plays a major role in the central component of hyperalgesia in this model of inflammation.

References

  1. Neuropharmacology. 2001 Jun;40(7):937-46 - PubMed
  2. Annu Rev Biochem. 2000;69:145-82 - PubMed
  3. Nature. 1995 Nov 23;378(6555):406-9 - PubMed
  4. FASEB J. 2001 Jul;15(9):1622-4 - PubMed
  5. Naunyn Schmiedebergs Arch Pharmacol. 2000 Jan;361(1):98-106 - PubMed
  6. J Pharmacol Exp Ther. 2005 Mar;312(3):1206-12 - PubMed
  7. J Pharmacol Exp Ther. 1999 Aug;290(2):551-60 - PubMed
  8. Eur J Pain. 1997;1(1):43-52 - PubMed
  9. Cancer Res. 2001 Dec 15;61(24):8617-23 - PubMed
  10. Genesis. 2006 Apr;44(4):177-82 - PubMed
  11. Br J Pharmacol. 1999 Oct;128(4):853-9 - PubMed
  12. Genesis. 2006 Mar;44(3):143-9 - PubMed
  13. J Pharmacol Exp Ther. 1997 Dec;283(3):1069-75 - PubMed
  14. Anesthesiology. 2007 May;106(5):1013-8 - PubMed
  15. Agents Actions. 1991 Mar;32(3-4):289-94 - PubMed
  16. Anesthesiology. 2004 Oct;101(4):983-90 - PubMed
  17. Mol Imaging Biol. 2003 Sep-Oct;5(5):286-303 - PubMed
  18. Pharmacol Res. 1989 Jul-Aug;21(4):375-84 - PubMed
  19. Mol Imaging Biol. 2006 May-Jun;8(3):171-87 - PubMed
  20. Neuroreport. 2002 Jan 21;13(1):93-6 - PubMed
  21. J Neurochem. 2003 Jul;86(2):318-28 - PubMed
  22. Life Sci. 2004 Oct 22;75(23):2807-17 - PubMed
  23. Br J Pharmacol. 1995 Jun;115(4):684-8 - PubMed
  24. Eur J Pharmacol. 2004 Apr 26;491(1):69-76 - PubMed
  25. Nature. 2001 Mar 22;410(6827):471-5 - PubMed
  26. J Neurosci. 2004 Mar 17;24(11):2727-32 - PubMed
  27. Inflamm Res. 2001 Feb;50(2):83-8 - PubMed
  28. Neuroscience. 1999;93(2):775-81 - PubMed
  29. Pain. 2003 Sep;105(1-2):47-55 - PubMed
  30. J Neurosci. 2000 Sep 1;20(17):6714-20 - PubMed
  31. Pain. 1988 Jan;32(1):77-88 - PubMed
  32. J Pharmacol Exp Ther. 1998 Jun;285(3):1031-8 - PubMed
  33. Br J Pharmacol. 2004 May;142(2):331-8 - PubMed
  34. J Biol Chem. 2004 Jun 4;279(23):24866-72 - PubMed
  35. Inflammopharmacology. 2004;12(1):57-68 - PubMed

Substances

MeSH terms

Publication Types

Grant support